Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Outlook For Reata's Bardoxolone Improves With Phase II Updates

Executive Summary

Latest data support moving bardoxolone into Phase III for autosomal dominant polycystic kidney disease (ADPKD).

Advertisement

Related Content

Reata Expands Options For Bardoxolone With New CKD Data
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Keeping Track: Good News/Bad News For Pfizer; Filings For Brexanolone, Risankizumab
Kyowa Hakko Kirin To Resume Development Of Kidney Disease Drug Bardoxolone Methyl In Japan
Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
Partners hit as Reata ends PhIII BEACON trial with bardoxolone in CKD
Abbott licenses Reata's CKD candidate outside the US for $450 million
Kyowa Kirin acquires Asian rights to Reata's lead drug

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel